Quantcast
Last updated on April 20, 2014 at 8:07 EDT

Latest Dopamine agonists Stories

2012-02-21 13:26:00

Cascade Study Raises Questions about Real Impact of Oregon's Prescription-Only Requirement PORTLAND, Ore., Feb. 21, 2012 /PRNewswire-USNewswire/ -- Cascade Policy Institute released a study today which found the 2005 Oregon law which restricts access to medicines containing pseudoephedrine (PSE) has not made the illegal drug methamphetamine harder to get or reduced the number of people using it. The Oregon law makes any medication containing PSE available only via prescription...

2012-01-26 06:55:00

(Ivanhoe Newswire) — More than 10 million people suffer from Parkinson´s disease worldwide. About 60,000 Americans are diagnosed with this disease every year. Scientists have long known that a major contributing factor of Parkinson´s disease is caused by a drop in dopamine — a much needed chemical for the brain. And for decades, people suffering with this disease have depended on a drug called Levodopa to boost their brain´s dopamine levels. Unfortunately,...

2012-01-26 02:06:14

Research breakthrough could improve the lives of millions Scientists at the Gladstone Institutes, an independent and nonprofit biomedical-research organization, have identified a protein that exacerbates symptoms of Parkinson's disease–a discovery that could one day lead to new treatments for people who suffer from this devastating neurodegenerative illness. In a paper being published online today in Neuron, Gladstone Investigator Anatol Kreitzer, PhD, and Talia Lerner, PhD, who...

2012-01-18 15:04:56

Since mephedrone was made illegal in the UK in 2010, the street price of the drug has risen while the quality has degraded, which in turn may have reduced use of the drug. New research published online today reveals that young people who continued to use mephedrone after it became illegal would switch to a new legal high if it were pure and rated highly by their friends or on the Internet. They would be less deterred by a lack of scientific research on the new drug. Mephedrone is a...

2011-11-09 06:00:00

NESS ZIONA, Israel, November 9, 2011 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ], Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet(R), Sinemet(R) CR or Stalevo(R), in patients with advanced Parkinson's disease. ND0611 is a proprietary carbidopa liquid formula administered sub-cutaneously via a dermal patch to increase the bioavailability and efficacy of orally- administered...

2011-11-04 20:57:13

Amphetamine use in adolescence can cause neurobiological imbalances and increase risk-taking behaviour, and these effects can persist into adulthood, even when subjects are drug free. These are the conclusions of a new study using animal models conducted by McGill University Health Centre (MUHC) researcher Dr. Gabriella Gobbi and her colleagues. The study, published today in The International Journal of Neuropsychopharmacology, is one of the first to shed light on how long-term amphetamine...

2011-10-31 10:11:38

A research team led by investigators at the Virginia Tech Carilion Research Institute has demonstrated the first rapid measurements of dopamine release in a human brain and provided preliminary evidence that the neurotransmitter can be tracked in its movement between brain cells while a subject expresses decision-making behavior. "In an experiment where we measured dopamine release while a subject made investment decisions in a stock market trading game, we showed that dopamine tracks...

2011-10-07 13:38:09

Parents of young caffeine consumers take heed: that high-calorie energy drink or soda might present more than just obesity risk. In fact, according to a double-blind, placebo-controlled study that examined responses to stimulants, an individual´s subjective response to caffeine may predict how he or she will respond to other stimulant drugs, possibly reflecting differences in risk for abuse of other more serious drugs of abuse, such as amphetamine and cocaine. The new findings are...

2011-09-28 06:00:00

EMERYVILLE, Calif., Sept. 28, 2011 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease. Called EASED(TM) (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia), this study will evaluate the safety and...

2011-08-29 08:39:00

RYE, N.Y., Aug. 29, 2011 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights. The data indicated that the amphetamine-injected C57BL/6 mice exhibited a dose dependent reduction in...